Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site
NCT ID: NCT07325864
Last Updated: 2026-01-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
25 participants
OBSERVATIONAL
2025-12-18
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prognostic Value of PD-L1 in NSCLC
NCT03078959
Detection of Early Metastases in Patients With Stage I Non-small Cell Lung Cancer
NCT00003006
Development and Application of Molecular Evaluation Instrument for Lung Cancer Diagnosis and Treatment
NCT06086587
A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced
NCT06467383
Evaluating the Predictive Capability of Transcriptomic Profiling for Identifying the Primary Site of Metastatic Tumors
NCT07319949
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site in patient diagnosed with NSCLC
To investigate the molecular differences between primitive lung cancer and the metastatic site.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* the operative risk is considered low based on respiratory reserve and cardiac assessment;
* the patient has clearly expressed willingness to adhere;
* availability of pathological material for tumor DNA extraction and NGS execution.
Exclusion Criteria
* Any other illness, metabolic disorder, physical examination, or laboratory findings that constitute a contraindication to study participation.
* Recent or ongoing severe or clinically significant infection.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Institute of Oncology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lorenzo Spaggiari
Role: PRINCIPAL_INVESTIGATOR
European Institute of Oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Istituto Europeo di Oncologia
Milan, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IEO 1956
Identifier Type: OTHER
Identifier Source: secondary_id
UID 4058
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.